Visit us at booth #813 and discover how you can empower your patients to be part of their wound treatment – literally.

Visit us at booth #813 and discover how you can empower your patients to be part of their wound treatment – literally.

The 3C Patch Wound Management System concentrates the body’s own living cells into a robust 3-layer patch to support wound healing.

Watch James McGuire, DPM, and Wound Center Director of the Temple University School of Podiatric Medicine, discussing the importance of autologous living cells in wound care.

3C Patch DINE & DEMO

Join us for dinner and an interactive 3C Patch workshop dedicated to healthcare specialists working on the front lines of chronic wound management.

Explore the innovative 3C Patch Wound Management System, the mode of action, and the clinical evidence. Learn about the practical aspects of implementing the 3C Patch Technology into the clinic workflow and the reimbursement process from fellow clinicians who are already using the 3C Patch in their wound care clinics.

3C Patch DINE & DEMO

Join us for dinner and an interactive 3C Patch workshop dedicated to healthcare specialists working on the front lines of chronic wound management.

Explore the innovative 3C Patch Wound Management System, the mode of action, and the clinical evidence. Learn about the practical aspects of implementing the 3C Patch Technology into the clinic workflow and the reimbursement process from fellow clinicians who are already using the 3C Patch in their wound care clinics.

Join us to learn about 3C Patch, a new personalized treatment option now available for chronic diabetic wounds.

1. 100% Autologous & Entirely alive
3C Patch represents a new category of advanced wound care modalities, different from current skin substitutes on the market. 3C Patch is a robust 3-layer leukocyte, platelet, and fibrin patch, created entirely from the patient’s own blood – nothing else. In-vitro studies have shown that the living cells in the 3C Patch can respond and adapt to the wound environment.

2. Clinically proven
3C Patch is backed by extensive clinical research, including a large (n=269), randomized, controlled trial published in The Lancet Diabetes & Endocrinology, 2018. The International Working Group of the Diabetic Foot recommends the use of 3C Patch – an autologous combined leukocyte, platelet, and fibrin patch as an adjunctive treatment in diabetic foot ulcers that are difficult to heal.

3. Implementation & Clinical Workflow
3C Patch is created through a fully automated centrifugation process that requires minimal hands-on time. We will dive into the practical aspects of implementing the 3C Patch in a busy clinic.

Date: Saturday, July 30

Time: 6 PM – 7:30 PM EST

Location: tbd

RESERVE YOUR SEAT

This session is complimentary for registered APMA Annual Scientific Meeting 2022 attendees. The event is intended for healthcare professionals working to heal patients with chronic wounds. To register for this event, please fill in the form below – the seats are limited. You will receive a confirmation email after you submitted the form.

For questions, please contact cc@reapplix.com.

I want to attend the 3C Patch DINE & DEMO Event

CLINICIAN

Philip Herbert patient

“Autologous wound care products are probably the future in wound care. 3C Patch® is a hassle-free point-of-care, autologous treatment that you create using a simple automated procedure and place on the wound immediately.“ Read more…

Wound Center Director of the Temple University School of Podiatric Medicine

PATIENT

Philip Herbert patient

“I have been told that I was going to have my foot taken off and because I have a metal plate in my ankle it would have meant amputating at the knee. 3C Patch® is absolutely amazing.” Read more…

Philip Herbert
54-year-old patient, West Yorkshire

WOUND CARE SERVICE LINE DIRECTOR

Frank Aviles
“The automated centrifugation process allows for minimal hands-on time, and the resulting patch is easy to apply. This, combined with the strong clinical evidence, were the main factors in trialing the product.” Read more…
Frank Aviles, PT, CWS, FACCWS, CLT
Natchitoches Regional Medical Center, Louisiana

ONLY THE PATIENT’S LIVING CELLS TO SIGNIFICANTLY INCREASE THE CHANCES OF HEALING1

Clinically proven to heal more diabetic chronic wounds faster 1

3C Patch® is backed by extensive clinical research, including a large (n=269), randomized controlled trial published in The Lancet Diabetes & Endocrinology, 2018, showing that 58% more patients healed with 3C Patch® compared to standard of care, and the time for healing was significantly shorter (p=0.0246).

The 3C Patch® System is FDA cleared and nationally covered by Medicare.

Diabetic wound treated with 3C Patch

Concentrating the body’s own living cells into heal into a robust 3-layer patch to support wound healing

3C Patch® draws on the body’s capacity to aid its own healing process. Made only from the patient’s own blood – nothing else, the entirely alive cells in 3C Patch® are continuously released. 3-5

3C Patch layers containing living cells

Living cells from the patient’s blood

The 3C Patch® continuously releases the patient’s own living cells – growth factors and immune cells– which can adapt to the wound environment3-5. They are known to give signals and orchestrate the wound healing process over time to get to wound closure.

3C Patch process at SAWC

Remarkably simple and readily available

3C Patch® is created through a completely automated centrifugation process, at the point of care. The 3C Patch® is ready when your patient needs it – the process takes approx. 15-20 min and the patch is placed on the wound immediately.

3C Patch is recommended by IWGDF

The International Working Group on the Diabetic Foot (IWGDF) recommends the use of the 3C Patch®, an autologous combined leukocyte, platelet, and fibrin patch, as an adjunctive treatment for non-infected diabetic foot ulcers that are difficult to heal.

IWGDF Guidelines

TEAM APMA 5K CHALLENGE

More than 1,700 runners and walkers have participated in the APMA 5K Run/Walk since its inception.

​Proceeds benefit the APMA Educational Foundation Student Scholarship Fund, which has given nearly $5 million in scholarships to podiatric medical students since 2005.

Sat July 30 – Tue August 2, 2022

Orlando, FL 32821 US

Reapplix is a Gold Sponsor for the Team APMA 5K Challenge – the race that supports the APMA Educational Foundation.

References

1. Game F., Jeffcoate W., Tarnow L., Jacobsen JL., Whitham DJ., Harrison EF., Ellender SJ., Fitzsimmons D., Löndahl M., LeucoPatch system for the management of hard-to-heal diabetic foot ulcers in the UK, Denmark, and Sweden: an observer-masked randomized controlled trial. Lancet Diabetes Endocrinology. 2018;6(11):870-878.

2. Löndahl, M., Tarnow, L., Karlsmark, T., Lundquist, R., Nielsen, A. M., Michelsen, M., Jørgensen, B. (2015). Use of an autologous leucocyte and platelet rich fibrin patch on hard-to-heal DFUs: a pilot study. Journal of Wound Care, 24(4), 172–8.

3. Lundquist, Jørgensen, Fagher, Löndahl (2015). 3C Patch™ – an adaptive triple layered autologous platelet and leukocyte rich fibrin patch and its clinical use in the treatment of hard-to-heal diabetic foot ulcers. Poster, Innovations in Wound Healing 2015.

4. Schmidt et al. (2019) “An autologous leukocyte and platelet-rich fibrin patch provides immune cells, cytokines and growth factors relevant for treating diabetic foot ulcers” Poster, ISDF 2019, The Hague, NL

5. Lundquist R et al. (2013). Characteristics of an autologous leukocyte and platelet-rich fibrin patch intended for the treatment of recalcitrant wounds. Wound Repair and Regeneration 21(1), 66–76